{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatic+Function&page=2",
    "query": {
      "condition": "Hepatic Function",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatic+Function&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-06T01:19:21.171Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00851227",
      "title": "Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Liver Disease",
        "Hyponatremia"
      ],
      "interventions": [
        {
          "name": "conivaptan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 26,
      "start_date": "2009-02",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2014-05-02",
      "last_synced_at": "2026-09-06T01:19:21.171Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00851227"
    },
    {
      "nct_id": "NCT04190654",
      "title": "Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "KW-6356",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 26,
      "start_date": "2019-11-26",
      "completion_date": "2020-03-20",
      "has_results": false,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-09-06T01:19:21.171Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Orlando, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04190654"
    },
    {
      "nct_id": "NCT04643795",
      "title": "Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment",
        "NASH - Nonalcoholic Steatohepatitis",
        "Cirrhosis, Liver"
      ],
      "interventions": [
        {
          "name": "MGL-3196",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Madrigal Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 87,
      "start_date": "2018-10-25",
      "completion_date": "2021-08-04",
      "has_results": false,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-09-06T01:19:21.171Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • Saint Paul, Minnesota • San Antonio, Texas",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04643795"
    },
    {
      "nct_id": "NCT03417778",
      "title": "Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Filgotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2018-04-03",
      "completion_date": "2018-08-09",
      "has_results": true,
      "last_update_posted_date": "2021-01-15",
      "last_synced_at": "2026-09-06T01:19:21.171Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03417778"
    },
    {
      "nct_id": "NCT02372084",
      "title": "A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "osilodrostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 33,
      "start_date": "2015-04-21",
      "completion_date": "2016-05-19",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-09-06T01:19:21.171Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Orlando, Florida • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02372084"
    },
    {
      "nct_id": "NCT07342868",
      "title": "Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Hepatitis B Infections"
      ],
      "interventions": [
        {
          "name": "Pevifoscorvir Sodium (ALG-000184)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aligos Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-01-30",
      "completion_date": "2026-08-19",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-06T01:19:21.171Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07342868"
    },
    {
      "nct_id": "NCT01187186",
      "title": "A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Liver Disease"
      ],
      "interventions": [
        {
          "name": "ASP1941",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 16,
      "start_date": "2010-05",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2010-10-07",
      "last_synced_at": "2026-09-06T01:19:21.171Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01187186"
    },
    {
      "nct_id": "NCT03870568",
      "title": "Functional Assessment in Liver Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cirrhosis",
        "End Stage Liver Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 411,
      "start_date": "2015-10-06",
      "completion_date": "2024-05-08",
      "has_results": false,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-09-06T01:19:21.171Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03870568"
    },
    {
      "nct_id": "NCT01875874",
      "title": "Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Liver Failure",
        "Fulminant Hepatic Failure",
        "Primary Graft Non-Function",
        "Surgically-Induced Liver Failure"
      ],
      "interventions": [
        {
          "name": "ELAD",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vital Therapies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2014-10",
      "completion_date": "2018-09",
      "has_results": true,
      "last_update_posted_date": "2019-02-12",
      "last_synced_at": "2026-09-06T01:19:21.171Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Weston",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01875874"
    },
    {
      "nct_id": "NCT06916078",
      "title": "A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Liver Dysfunction",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Lepodisiran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-04-23",
      "completion_date": "2026-07-13",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-06T01:19:21.171Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Orlando, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06916078"
    }
  ]
}